Tivic Health Systems (TIVC)
NASDAQ:TIVC
TIVC Stock Chart & Stats
$1.38
>-$0.01(-2.18%)
At close: 4:00 PM EST
$1.38
>-$0.01(-2.18%)
Day’s Range― - ―
52-Week Range$0.72 - $13.23
Previous CloseN/A
Volume226.20K
Average Volume (3M)99.84K
Market Cap
$2.55M
Enterprise Value$1.09M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.96
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,877,926
10 Day Avg. Volume91,463
30 Day Avg. Volume99,839
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)1.09
P/FCF Ratio-1.10
Enterprise Value/Market Cap0.43
Enterprise Value/Revenue2.86
Enterprise Value/Gross Profit34.19
Enterprise Value/Ebitda-1.42
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strategic Pivot To Biopharma (Entolimod Development)Tivic's deliberate shift from consumer bioelectronics to a focused biopharma strategy centered on Entolimod creates a clearer product roadmap and capital allocation. IND transfers and development readiness materially de-risk clinical progression, positioning the company for durable upside from government stockpiles and oncology supportive-care markets.
Vertical Integration Via Velocity Bioworks CDMOOwning an in-house CDMO and proving a 200x scale-up provides lasting operational advantages: lower COGS, faster scale for pivotal programs, and eligibility for government procurement requiring domestic supply. It also creates a durable diversification path by selling contract manufacturing services to third parties.
Government Partnerships And Funded Preclinical ProgramsActive collaborations with NIAID, BARDA and NIH provide structural validation and potential non-dilutive funding. Government-sponsored studies and interest in stockpiling raise the probability of milestone-based support and procurement paths that can materially reduce financing needs and accelerate commercial adoption for countermeasure indications.
Bears Say
Severely Eroded Balance Sheet And Equity BaseThe dramatic decline in assets and collapse of equity materially weakens financial resilience. With little residual capital cushion, the company faces higher insolvency and covenant risk, reduced strategic optionality, and greater dependence on external financing to fund expensive clinical and manufacturing milestones over the next 2–6 months.
Persistent Negative Operating Cash Flow And Cash BurnContinued negative cash generation, even if improving in magnitude, signals the business cannot self-fund development or manufacturing scale. This structural cash burn increases reliance on capital markets or partners, raising execution risk if funding terms deteriorate and potentially delaying trials or commercialization timelines.
Market And Governance Risks That Hinder Capital AccessA Nasdaq minimum bid notice and prior failed shareholder meeting indicate weak investor engagement and governance friction. These structural market-access risks can limit liquidity, complicate equity raises, and increase financing costs or dilution over the medium term, constraining the company’s ability to execute its biopharma strategy.
Tivic Health Systems News
TIVC FAQ
What was Tivic Health Systems’s price range in the past 12 months?
Tivic Health Systems lowest stock price was $0.72 and its highest was $13.23 in the past 12 months.
What is Tivic Health Systems’s market cap?
Tivic Health Systems’s market cap is $2.55M.
When is Tivic Health Systems’s upcoming earnings report date?
Tivic Health Systems’s upcoming earnings report date is May 18, 2026 which is in 46 days.
How were Tivic Health Systems’s earnings last quarter?
Currently, no data Available
Is Tivic Health Systems overvalued?
According to Wall Street analysts Tivic Health Systems’s price is currently Overvalued.
Does Tivic Health Systems pay dividends?
Tivic Health Systems does not currently pay dividends.
What is Tivic Health Systems’s EPS estimate?
Tivic Health Systems’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tivic Health Systems have?
Tivic Health Systems has 2,877,926 shares outstanding.
What happened to Tivic Health Systems’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tivic Health Systems?
Currently, no hedge funds are holding shares in TIVC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tivic Health Systems
Tivic Health Systems Inc. operates as a bioelectronic device company that delivers non-invasive neuromodulation products for the treatment of inflammatory conditions. Its primary product is ClearUP, is a medical device intended to relieve sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, including BestBuy.com and FSAStore.com. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.
TIVC Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Tivic Health demonstrated substantial progress in its strategic transformation and development of Entolimod, improving its financial position despite experiencing increased net loss and manufacturing delays.View all TIVC earnings summariesTechnical Analysis
Ownership Overview
1.66% Insiders
0.28% Mutual Funds
7.65% Other Institutional Investors
90.34% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---